[go: up one dir, main page]

SI2276473T1 - Gastro retencijsko dajanje zdravila karbidope/levodope - Google Patents

Gastro retencijsko dajanje zdravila karbidope/levodope

Info

Publication number
SI2276473T1
SI2276473T1 SI200931553T SI200931553T SI2276473T1 SI 2276473 T1 SI2276473 T1 SI 2276473T1 SI 200931553 T SI200931553 T SI 200931553T SI 200931553 T SI200931553 T SI 200931553T SI 2276473 T1 SI2276473 T1 SI 2276473T1
Authority
SI
Slovenia
Prior art keywords
carbidopa
levodopa
drug delivery
gastroretentive drug
gastroretentive
Prior art date
Application number
SI200931553T
Other languages
English (en)
Inventor
Nadav Navon
Eytan Moor
David Kirmayer
Elena Kluev
Giora Carni
Original Assignee
Intec Pharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intec Pharma Ltd. filed Critical Intec Pharma Ltd.
Publication of SI2276473T1 publication Critical patent/SI2276473T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SI200931553T 2008-04-18 2009-04-17 Gastro retencijsko dajanje zdravila karbidope/levodope SI2276473T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4626108P 2008-04-18 2008-04-18
US12005108P 2008-12-04 2008-12-04
EP09754186.6A EP2276473B1 (en) 2008-04-18 2009-04-17 Gastroretentive drug delivery for carbidopa/levodopa
PCT/IB2009/005691 WO2009144558A1 (en) 2008-04-18 2009-04-17 Carbidopa/lipodopa gastroretentive drug delivery

Publications (1)

Publication Number Publication Date
SI2276473T1 true SI2276473T1 (sl) 2017-02-28

Family

ID=41376643

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931553T SI2276473T1 (sl) 2008-04-18 2009-04-17 Gastro retencijsko dajanje zdravila karbidope/levodope

Country Status (19)

Country Link
US (6) US8771730B2 (sl)
EP (2) EP3115043B1 (sl)
JP (2) JP2011518148A (sl)
KR (1) KR101601649B1 (sl)
CN (2) CN106176678A (sl)
CA (1) CA2721493C (sl)
CY (1) CY1118296T1 (sl)
DK (1) DK2276473T3 (sl)
ES (2) ES2606395T3 (sl)
HK (1) HK1158545A1 (sl)
HR (1) HRP20161433T1 (sl)
HU (1) HUE030958T2 (sl)
IL (2) IL208708A (sl)
LT (1) LT2276473T (sl)
PL (1) PL2276473T3 (sl)
PT (1) PT2276473T (sl)
SI (1) SI2276473T1 (sl)
WO (1) WO2009144558A1 (sl)
ZA (1) ZA201007797B (sl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2276473T1 (sl) 2008-04-18 2017-02-28 Intec Pharma Ltd. Gastro retencijsko dajanje zdravila karbidope/levodope
AU2009281752B2 (en) 2008-08-15 2016-11-17 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
CA2815959C (en) 2010-11-01 2020-10-06 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
US10150792B2 (en) * 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
WO2014099056A2 (en) 2012-12-20 2014-06-26 Carnegie Mellon University Methods and materials for reducing organ transplant rejection or ischemic/reperfusion injury in a subject
CN106535878B (zh) 2014-06-02 2022-11-01 科莱西奥生物科技有限公司 可张开的胃内滞留剂型
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
WO2015191922A1 (en) 2014-06-11 2015-12-17 Massachusetts Institute Of Technology Enteric elastomers
DE102014119576A1 (de) 2014-12-23 2016-06-23 Ernst-Moritz-Arndt-Universität Greifswald Pharmazeutische Arzneimittelform zur Applikation auf Schleimhäuten
US10035799B2 (en) 2015-01-30 2018-07-31 Lieber Institute For Brain Development COMT inhibiting methods and compositions
WO2016134134A1 (en) * 2015-02-19 2016-08-25 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
CA2987114A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Method of 3d printing oral dosage forms having a drug in a compartment sealed by an erodible plug
CN107920997A (zh) * 2015-06-17 2018-04-17 比奥根Ma公司 富马酸二甲酯颗粒和其药物组合物
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
CN108472249A (zh) 2015-10-23 2018-08-31 林德拉有限公司 用于治疗剂缓释的胃驻留系统及其使用方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
HUE056356T2 (hu) * 2015-11-25 2022-02-28 Lieber Inst Inc Tetrahidro-8H-pirido[1,2-a]pirazin-8-on vegyületek, mint COMT inhibitorok neurodegeneratív rendellenességek kezelésére
EP3383365A1 (en) * 2015-12-01 2018-10-10 Clexio Biosciences Ltd. Gastric retentive devices
EP3386488B1 (en) 2015-12-08 2023-09-06 Lyndra Therapeutics, Inc. Geometric configurations for gastric residence systems
AU2017268840B2 (en) 2016-05-27 2022-02-10 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
US11975104B2 (en) 2016-07-11 2024-05-07 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
RU2019103297A (ru) * 2016-07-11 2020-08-11 Интек Фарма Лтд. Гастроретентивные составы для перорального введения и пути их применения
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
EP3320898A1 (en) 2016-11-11 2018-05-16 ratiopharm GmbH Dosage form comprising a carrier structure and method for manufacturing the dosage form
CN110035718B (zh) 2016-12-02 2021-04-06 克雷西奥生物科技有限公司 胃内滞留系统
CA3051614A1 (en) 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US11547839B2 (en) 2017-12-04 2023-01-10 Clexio Biosciences Ltd. Long acting gastric residence system
WO2019137200A1 (en) 2018-01-09 2019-07-18 Triastek, Inc. Oral drug dosage forms comprising a fixed-dose of an adhd non-stimulant and an adhd stimulant
US12083303B2 (en) 2019-01-21 2024-09-10 Vibrant Ltd. Device and method for delivering a flowable ingestible medicament into the gastrointestinal tract of a user
US11638678B1 (en) 2018-04-09 2023-05-02 Vibrant Ltd. Vibrating capsule system and treatment method
WO2020141469A1 (en) 2019-01-03 2020-07-09 Vibrant Ltd. Device and method for delivering an ingestible medicament into the gastrointestinal tract of a user
US11510590B1 (en) 2018-05-07 2022-11-29 Vibrant Ltd. Methods and systems for treating gastrointestinal disorders
WO2019245925A1 (en) 2018-06-19 2019-12-26 National University Of Singapore Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications
GB201901470D0 (en) 2019-02-04 2019-03-27 Vibrant Ltd Vibrating capsule for gastrointestinal treatment, and method of use thereof
US11147767B2 (en) * 2019-02-25 2021-10-19 Rubicon Research Private Limited Gastroretentive formulations
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
EP3989939A4 (en) * 2019-06-28 2023-07-19 Dynamic Biologics Inc. POLYMER CONJUGATE OF LEVODOPA, CORRESPONDING FORMULATIONS, AND THEIR USES FOR THE TREATMENT OF PARKINSON'S DISEASE
CN113116846B (zh) * 2019-12-31 2024-03-19 广州玻思韬控释药业有限公司 胃滞留片
JP7525935B2 (ja) * 2020-03-02 2024-07-31 クラフト ヘルス プライベート リミテッド 持続的薬物放出のための経口剤形の製造方法
US11986449B2 (en) * 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
KR20240039030A (ko) 2021-07-30 2024-03-26 에벡시아 테라퓨틱스 아이엔씨. 5-하이드록시트립토판 위체류성 투여 형태
JP2024535585A (ja) 2021-10-14 2024-09-30 エヴェクシア セラピューティクス， インク． 脳内５－ヒドロキシトリプタミンの機能を治療目的で最適化する方法
WO2024024865A1 (ja) * 2022-07-28 2024-02-01 大原薬品工業株式会社 レボドパ持続性製剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4767627A (en) * 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
JPH03163011A (ja) 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
EP1064937A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
GB9930578D0 (en) * 1999-12-23 2000-02-16 Smithkline Beecham Plc Pharmaceutical formulations
DE10004790B4 (de) 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
DE60237372D1 (de) 2001-07-04 2010-09-30 Sun Pharma Advanced Res Co Ltd Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1523981A1 (en) 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
US20050244517A1 (en) 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
IL166183A0 (en) * 2005-01-06 2006-01-15 Yissum Res Dev Co Novel diagnostic and imaging techniques of the gi tract
EP1981465B1 (en) * 2006-01-18 2015-11-04 Intec Pharma Ltd. Method for forming delivery devices for oral intake of an agent
CA2642479C (en) 2006-02-15 2014-08-19 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
EP1970056A1 (en) 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
SI2276473T1 (sl) * 2008-04-18 2017-02-28 Intec Pharma Ltd. Gastro retencijsko dajanje zdravila karbidope/levodope
CN101309436B (zh) 2008-07-02 2012-04-18 三一重工股份有限公司 一种无线通信设备匹配认证方法、装置及系统
AU2009281752B2 (en) 2008-08-15 2016-11-17 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
JP2012510987A (ja) 2008-12-04 2012-05-17 インテック ファーマ リミテッド ザレプロン胃内滞留性薬剤送達システム
CA2815959C (en) 2010-11-01 2020-10-06 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
US20120288551A1 (en) * 2011-05-10 2012-11-15 Antecip Bioventures Ii Llc Implantable Polymeric Device for Sustained Release of Sufentanil

Also Published As

Publication number Publication date
KR20110015549A (ko) 2011-02-16
IL245605A0 (en) 2016-06-30
EP3115043B1 (en) 2020-11-25
IL208708A0 (en) 2010-12-30
CA2721493C (en) 2017-11-28
US20110117192A1 (en) 2011-05-19
CY1118296T1 (el) 2017-06-28
EP2276473A1 (en) 2011-01-26
HK1158545A1 (zh) 2012-07-20
HRP20161433T1 (hr) 2017-01-27
PL2276473T3 (pl) 2017-03-31
HUE030958T2 (en) 2017-06-28
US20160199300A1 (en) 2016-07-14
ES2849873T3 (es) 2021-08-23
DK2276473T3 (en) 2017-01-09
PT2276473T (pt) 2016-12-15
US9554991B2 (en) 2017-01-31
US9072663B2 (en) 2015-07-07
JP2015154934A (ja) 2015-08-27
US8771730B2 (en) 2014-07-08
EP2276473B1 (en) 2016-09-14
LT2276473T (lt) 2017-02-27
US20150366832A1 (en) 2015-12-24
US20170119664A1 (en) 2017-05-04
JP6062465B2 (ja) 2017-01-18
IL208708A (en) 2016-05-31
EP3115043A1 (en) 2017-01-11
US20140314842A1 (en) 2014-10-23
ES2606395T3 (es) 2017-03-23
CN102149369B (zh) 2016-08-10
ZA201007797B (en) 2011-07-27
CN102149369A (zh) 2011-08-10
EP2276473A4 (en) 2013-11-06
CN106176678A (zh) 2016-12-07
WO2009144558A1 (en) 2009-12-03
CA2721493A1 (en) 2009-12-03
JP2011518148A (ja) 2011-06-23
KR101601649B1 (ko) 2016-03-09
US20150010624A1 (en) 2015-01-08
US9259387B2 (en) 2016-02-16

Similar Documents

Publication Publication Date Title
PT2276473T (pt) Entrega de fármacos gastro-retentiva para carbidopa/levodopa
ZA201104620B (en) Zaleplon gastroretentive drug delivery system
HK1218874A1 (zh) 真皮遞送
IL215608A0 (en) Drug delivery composition
SG2014007389A (en) Posterior segment drug delivery
EP2339973A4 (en) ACTIVE RELEASE IMPLANTS
IL216383A (en) Stable pharmaceutical preparations containing arginine, levodopa and carbidopa
PL2307079T3 (pl) Urządzenie do podawania leku
ZA200903854B (en) A gastroretentive pharmaceutical dosage form
IL210735A0 (en) Pharmaceutical composition
EP2323587A4 (en) ACTIVE RELEASE IMPLANTS
IL213577A0 (en) Drug delivery device
IL208387A0 (en) Pharmaceutical composition
HU0800591D0 (en) Stable pharmaceutical combination
EP2328511A4 (en) ACTIVE RELEASE IMPLANTS
GB0803054D0 (en) Medicament
IL207734A0 (en) Pharmaceutical composition
GB2464200B (en) Pharmaceutical composition
GB0817969D0 (en) Pharmaceutical composition
HK1252214A1 (zh) 雙氯芬酸製劑
HK1182939A1 (en) Stable pharmaceutical composition
IL212005A0 (en) Novel gastroretentive delivery system
PL385631A1 (pl) Pompa perystaltyczna
GB0814986D0 (en) Peptide for il10 production
GB0803395D0 (en) Medicament